Multi-Mode Assessment Approach on Anti-Cancer Potency of Vanadium on Breast Cancer Cells

Year 2018, Volume: 77 Issue: 2, 47 - 54, 02.12.2018

Canan Vejselova Sezer

Abstract

DOI: 10.26650/EurJBiol.2018.18007

Objective: The anti-cancer activities of
vanadium and its compounds have been widely investigated in cancer research
recently. This is mainly attributed to vanadium and its compounds’ near ideal
properties for being an anti-cancer agent. Most of the current classical
chemotherapeutics used in cancer therapy are known to bring numerous strong
side effects. Thus, there is a need to discover new drugs which have mild or no
side effects and which are effective in low doses. For the treatment of breast
cancer (a disease with a difficult and costly treatment process, high
mortality, and which is especially prevalent in woman), novel drugs and
approaches are required. With this in mind, this study investigates the
potential therapeutic efficacies of vanadyl sulphate, a member of the vanadium
compounds with ideal anti-cancer properties such as cytotoxicity,
antiproliferative and proapoptotic activities on human breast adenocarcinoma
cells (MCF-7) including morphological and ultrastructural changes.

Materials and Methods: A MTT colorimetric
assay was used for cell viability assessment. Morphological and ultrastructural
changes were evaluated using confocal and transmission electron microscopy
methods, respectively. The apoptosis stimulating property of vanadyl sulphate
was tested under a flow cytometry. And also, cell cycle and proliferation
inhibitory effects were examined using the immunohistochemistry technique. 

Keywords

Breast cancer, vanadium, cytotoxic activity

References

• 1. Siegel RL, Miller KD, Jemal A. Cancer statistics. Ca Cancer J Clin 2015; 65(1): 5-29. 2. Mobasheri A, Barrett-Jolley R. Aquaporin water channels in the mammary gland: From physiology to pathophysiology and neoplasia. J Mammary Gland Biol Neoplasia 2014;19(1): 91-102. 3. Harris HR, Bergkvist L, Wolk A. Adherence to the world cancer research fund/American Institute for Cancer Research recommendations and breast cancer risk. Int J Cancer 2016; 138(11): 2657-64. 4. Rillema JA. Development of the mammary gland and lactation. Trends Endocrinol Metab 1994; 5(4): 149-54. 5. Petanidis S, Kioseoglou E, Hadzopoulou-Cladaras M, Salifoglou A. Novel ternary vanadium-betaine-peroxido species suppresses H-ras and matrix metalloproteinase-2 expression by increasing reactive oxygen species-mediated apoptosis in cancer cells. Cancer Lett 2013; 335(2): 387-96. 6. Gruzewska K, Michno A, Pawelczyk T, Bielarczyk H. Essentiality and toxicity of vanadium supplements in health and pathology. J Physiol Pharmacol 2014; 65(5): 603-11. 7. Bishayee A, Waghray A, Patel MA, Chatterjee M. Vanadium in the detection, prevention and treatment of cancer: The in vivo evidence. Cancer Lett 2010; 294(1): 1-12. 8. Gonzalez-Villalva A, Pinon-Zarate G, De la Pena Diaz A, Flores-García M, Bizarro-Nevares P, Rendón-Huerta EP, et al. The effect of vanadium on platelet function. Environ Toxicol Pharmacol 2011; 32(3): 447-56. 9. Evangelou AM. Vanadium in cancer treatment. Critical Rev Oncol Hematol 2002; 42(3): 249-65. 10. Ekert PG, Vaux DL. Apoptosis and the immune system. Br Med Bulletin 1997; 53(3): 591-603. 11. Kostova I. Titanium and vanadium complexes as anticancer agents. Anticancer Agents Med Chem 2009; 9(8): 827-42. 12. Korbecki J, Baranowska-Bosiacka I, Gutowska I, Chlubek D. Biochemical and medical importance of vanadium compounds. Acta Biochim Pol 2012; 59(2): 195-200. 13. Liem DA, Gho CC, Gho BC, Kazim S, Manintveld OC, Verdouw PD, et al. The tyrosine phosphatase inhibitor bis(maltolato)-oxovanadium attenuates myocardial reperfusion injury by opening ATP-sensitive potassium channels. J Pharmacol Exp Ther 2004; 309(3): 1256-62. 14. Abakumova OY, Podobed OV, Belayeva NF, Tochilkin AI. Anticancer activity of oxovanadium compounds. Biomed Khim 2012; 6(2): 164-70. 15. Capella LS, Alcantara JS, Maura-Neto V, Lopes AG, Capella MA. Vanadate is toxic to adherent-growing multidrug-resistant cells. Tumor Biol 2000; 21(1): 54-62. 16. Suzuki T, Fujikura K, Higashiyama T, Takata K. DNA staining for fluorescence and laser confocal microscopy. J Histochem Cytochem 1997; 45(1): 49-53. 17. Canel M, Serrels A, Frame MC, Brunton VG. E-Cadherin-integrin crosstalk in cancer invasion and metastasis. J Cell Sci 2013; 126(Pt 2): 393-401. 18. Glauert AM, Lewis PR. Biological specimen preparation for transmission electron microscopy. Princeton University Press, New Jersey, 1998; ISBN: 0-691-00749-2 (Cloth), ISBN: 0-691-00900-7 (pbk). 19. Yamaguchi T, Watanabe S, Matsumura Y, Tokuoka Y, Yokoyama A. Oxovanadium complexes with quinoline and pyridinone ligands: Syntheses of the complexes and effect of alkyl chains on their apoptosis-inducing activity in leukemia cells. Bioorganic Med Chem 2012; 20(9): 3058-64. 20. Berx G, Van Roy F. Commentary: The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res 2001; 3(5): 289-93. 21. Holko P, Ligeza J, Kisielewska J, Kordowiak AM, Klein A. The effect of vanadyl sulphate (VOSO4) on autocrine growth on human epithelial cancer cell lines. Pol J Pathol 2008; 59(1): 3-8. 22. Tadakuma T, Kizaki H, Odaka C, Kubota R, Ishimura Y, Yagita H, et al. CD4+CD8+ thymocytes are susceptible to DNA fragmentation induced by phorbol ester, calcium ionophore and anti-CD3 antibody. Eur J Immunol 1990; 20(4): 779-84. 23. McConkey DJ, Hartzell P, Amador-Perez FJ, Orenius S, Jondal M. Calcium-dependent killing of immature thymocytes by stimulation via CD37T cell receptor complex. J Immunol 1989; 143(6): 1801-6. 24. Varecka L, Peterajova E, Sevcik J. Ca(2+)-activated K+ channel and the activation of Ca2+ influx in vanadate-treated red blood cells. Gen Physiol Biophys 1997; 16(4): 339-57. 25. Kordowiak AM, Klein A, Goc A, Dabroś W. Comparison of the effect of VOSO4, Na3VO4 and NaVO3 on proliferation, viability and morphology of H35-19 rat hepatoma cell line. Pol J Pathol 2007; 58(1): 51-7. 26. León IE, Cadavid Vargas JF, Tiscornia I, Porro V, Castelli S, Katkar P, et al. Oxidovanadium(IV) complexes with chrysin and silibinin: anticancer activity and mechanisms of action in a human colon adenocarcinoma model. J Biol Inorg Chem 2015; 20(7): 1175-91. 27. Umbas R, Schalken JA, Aalders TW, Carter BS, Karthaus HF, Schaafsma HE, et al. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 1994; 52(18): 5104-09. 28. Oka H, Shiozaki H, Kobayashi K, Inoue M, Tahara H, Kobayashi T, et al. Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Research 1993; 53(7): 1696-01. 29. Molinuevo MS, Cortizo AM, Etcheverry SB. Vanadium (IV) complexes inhibit adhesion, migration and colony formation of UMR106 osteosarcoma cells. Cancer Chemother Pharmacol 2008; 61(5): 767-73.